Ferring Bravelle approval
This article was originally published in Pharmaceutical Approvals Monthly
Executive SummaryFerring's highly purified, human-derived follicle-stimulating hormone (FSH) urofollitropin will be priced 25% to 35% lower than other FSH therapies on the market, including recombinant products such as Serono's Gonal-F and Organon's Follistim, the firm says. Bravelle, available in subcutaneous and intramuscular injections, cleared FDA May 6 for induction of ovulation. An application for use in in vitro fertilization was submitted earlier this yea
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.